Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis

NCT04879628 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04879628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04879628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 7, 2021
Completion date
August 23, 2027
Enrollment
129 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis